Abstract
AimsThe optimal timing of intervention in non-ST-elevation myocardial infarction (NSTEMI) remains uncertain. The aim of this multicentre trial was to assess whether an immediate invasive approach is superior to an early invasive or a selective invasive approach with respect to reduction of large infarction. Methods and resultsPatients with NSTEMI were randomized to either an immediate (<2 h after randomization; n = 201), an early (1048 h after randomization; n = 200), or a selective invasive approach with high invasive percentage (n = 201). The primary outcome was the peak creatine kinase (CK)-myocardial band (MB) activity during index hospitalization; key secondary clinical endpoints were the composite of (i) death and non-fatal infarction; (ii) death, non-fatal infarction, and refractory ischaemia; (iii) death, non-fatal infarction, refractory ischaemia, and rehospitalization for unstable angina within 6 months.The median time from randomization to angiography was 1.1 h in the immediate vs. 18.6 h in the early and 67.2 h in the selective invasive group (P< 0.001). There was no significant difference in the peak CK-MB activity between groups. The key secondary clinical endpoints were similar between groups at 6-month follow-up: death and infarction: 21.0 vs. 16.0 vs. 14.5; P = 0.17; death, infarction, refractory ischaemia: 20.9 vs. 21.5 vs. 22.0; P = 0.98; death, infarction, refractory ischaemia, rehospitalization: 26.0 vs. 26.5 vs. 24.5; P = 0.91, respectively. ConclusionsIn NSTEMI patients, an immediate invasive approach does not offer an advantage over an early or a selective invasive approach with respect to large myocardial infarctions as defined by peak CK-MB levels, which is supported by similar clinical outcomes.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | European Heart Journal |
| Jahrgang | 33 |
| Ausgabenummer | 16 |
| Seiten (von - bis) | 2035-2043 |
| Seitenumfang | 9 |
| ISSN | 0195-668X |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 08.2012 |
Fördermittel
The study was supported in part by free tirofiban medication from MSD SHARP & DOHME GmbH, Germany, and Iroko Pharmaceuticals, LLC, PA, USA.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Zentren: Universitäres Herzzentrum Lübeck (UHZL)
DFG-Fachsystematik
- 2.22-12 Kardiologie, Angiologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: The Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial)“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver